Pharmacokinetic of procainamide in man.
作者信息
Koch-Weser J
出版信息
Ann N Y Acad Sci. 1971 Jul 6;179:370-82. doi: 10.1111/j.1749-6632.1971.tb46914.x.
Abstract
摘要
相似文献
1
Pharmacokinetic of procainamide in man.普鲁卡因酰胺在人体中的药代动力学。
Ann N Y Acad Sci. 1971 Jul 6;179:370-82. doi: 10.1111/j.1749-6632.1971.tb46914.x.
2
Clinical application of the pharmacokinetics of procaine amide.
Cardiovasc Clin. 1974;6(2):63-75.
3
Dosage, plasms concentration and antiarrhythmic effect of procainamide in sustained-release tablets.
Acta Med Scand. 1974 Mar;195(3):217-22. doi: 10.1111/j.0954-6820.1974.tb08125.x.
4
Letter: Time-dependent effect of oral procainamide in patients with exertional arrhythmias.
J Pharm Sci. 1974 Dec;63(12):1958-9. doi: 10.1002/jps.2600631231.
5
Conventional and sustained-release procainamide: update on pharmacology and clinical use.
Clin Ther. 1985;7(5):618-40.
6
A new sustained-release tablet formulation of procainamide.
Eur J Clin Pharmacol. 1973 Dec;6(4):251-5. doi: 10.1007/BF00644741.
7
Procainamide acetylation and disposition in dialysis patients.透析患者中普鲁卡因胺的乙酰化作用及处置情况
Clin Invest Med. 1979;2(1):5-11.
8
The clinical use of procainamide.
Am J Hosp Pharm. 1974 Sep;31(9):889-91.
9
[Procain amide and phenytoin as anti-arrhythmia agents, some dosage principles].
Tidsskr Nor Laegeforen. 1974 Jun 30;94(18):1198-200.
10
Procainamide in the dog: antiarrhythmic plasma concentrations after intravenous administration.
J Vet Pharmacol Ther. 1986 Dec;9(4):359-69. doi: 10.1111/j.1365-2885.1986.tb00056.x.
引用本文的文献
1
The stable isotope method for determining absolute bioavailability.用于测定绝对生物利用度的稳定同位素法。
Transl Clin Pharmacol. 2017 Jun;25(2):53-58. doi: 10.12793/tcp.2017.25.2.53. Epub 2017 Jun 15.
2
Decreased vancomycin clearance in patients with congestive heart failure.充血性心力衰竭患者的万古霉素清除率降低。
Eur J Clin Pharmacol. 2013 Mar;69(3):449-57. doi: 10.1007/s00228-012-1340-4. Epub 2012 Jul 12.
3
Metabolomics reveals the metabolic map of procainamide in humans and mice.代谢组学揭示了普鲁卡因胺在人类和小鼠中的代谢图谱。
Biochem Pharmacol. 2012 May 15;83(10):1435-44. doi: 10.1016/j.bcp.2012.02.013. Epub 2012 Feb 24.
4
Acetylator phenotype and the clinical pharmacology of slow-release procainamide.乙酰化表型与普鲁卡因胺控释剂的临床药理学。
Br J Clin Pharmacol. 1976 Dec;3(6):1023-6. doi: 10.1111/j.1365-2125.1976.tb00352.x.
5
Therapeutic drug monitoring of antiarrhythmic drugs.抗心律失常药物的治疗药物监测
Clin Pharmacokinet. 2003;42(7):647-63. doi: 10.2165/00003088-200342070-00004.
6
Model parameter estimation and analysis: understanding parametric structure.
Ann Biomed Eng. 1994 Jan-Feb;22(1):97-111. doi: 10.1007/BF02368226.
7
The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.以缓释剂型给予急性心肌梗死患者的5-单硝酸异山梨酯（5-ISMN）的血浆浓度。
Br J Clin Pharmacol. 1995 Jun;39(6):704-8. doi: 10.1111/j.1365-2125.1995.tb05733.x.
8
Analysis of the contributions of permeability and flow of intercompartmental clearance.分析隔室间清除率的通透性和流量的贡献。
J Pharmacokinet Biopharm. 1981 Apr;9(2):167-80. doi: 10.1007/BF01068080.
9
Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure.丙吡胺在近期发生至中度心力衰竭患者中的药代动力学。
Eur J Clin Pharmacol. 1981 Feb;19(3):187-92. doi: 10.1007/BF00561947.
10
Disopyramide pharmacokinetics during recovery from myocardial infarction.心肌梗死恢复期的丙吡胺药代动力学。
Br J Clin Pharmacol. 1982 Mar;13(3):417-21. doi: 10.1111/j.1365-2125.1982.tb01395.x.
Zotero 插件